New drugs should be judged on "willingness to pay" basis, says leading economist.
Wise
Jacqui
J
D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000188:drug therapy; D006301:Health Services Needs and Demand / Q000191:economics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics; D055553:Prescription Drugs / Q000191:economics*
D007004:Hypoglycemic Agents; D055553:Prescription Drugs